Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
EVE Health Group Limited ( (AU:EVE) ) has provided an announcement.
EVE Health Group Limited has announced the launch of two innovative products, Dyspro and Libbo, targeting the global dysmenorrhoea and erectile dysfunction markets, valued at US$10.92B and US$5.31B respectively. With its patent-pending nano-emulsion technology, the company aims to improve drug delivery speed and effectiveness, having already commenced sales of Dyspro in Australia, with Libbo expected to follow in December.
More about EVE Health Group Limited
EVE Health Group Limited is an emerging pharmaceutical company specializing in fast-acting drug delivery technology. The company focuses on disrupting the underserved women’s health market and has a strong pipeline that includes solutions for men’s health.
Average Trading Volume: 414,510
Technical Sentiment Signal: Sell
Current Market Cap: A$8.12M
For an in-depth examination of EVE stock, go to TipRanks’ Overview page.